Search Videos and More
News
Dana-Farber Researchers Present Key Studies at ASCO Annual Meeting
Dana-Farber Cancer Institute researchers are presenting dozens of research studies at the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO). The studies will be presented during the virtual program on June 4-8, 2021. ASCO is the world’s largest clinical cancer research meeting, attracting more than 30,000 oncology professionals from around the world.
News
Immunotherapy Combination Shows Benefit for Patients with Advanced Melanoma, Phase 3 Trial Shows
A combination of two drugs that target different proteins on immune system T cells kept advanced melanoma in check significantly longer than one of the drugs alone in a phase 3 clinical trial involving 714 patients. Dana-Farber Cancer Institute investigators co-led the study. Findings will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually June 4-8, 2021, and are included in the ASCO press program.
Document
Melanoma Select Clinical Trials
The listed trials are a sampling of our many open and accruing studies.
News
Targeted Agent Shows Early Promise Against a Dangerous Infant Leukemia
Leukemias involving reshuffling or rearrangement of the mixed lineage leukemia (MLL) gene, known as MLL-rearranged or MLL-r leukemias, account for 70 to 80 percent of acute leukemias in infants under one year old. In these blood cancers, a subset of acute myeloid and acute lymphoid leukemias (AML and ALL), the MLL gene breaks and reattaches to the wrong section of the chromosome.
News
Looking for Cancer’s Achilles Heel: The Pediatric Cancer Dependency Map
Thanks to developments in precision medicine, some adult cancers are now treated with designer drugs that target the genetic mutations that caused them. But most children with cancer have not reaped the same benefits. Unlike adult cancers, childhood cancers carry few genetic mutations.
News
Researchers Focus on How to Invigorate ‘Exhausted’ T-Cells in Immunotherapy
Despite the sometimes-dramatic success of new cancer immunotherapies like checkpoint inhibitor drugs and CAR T cells, thus far only a minority of patients have responded or gained long-lasting benefits.
News
mRNA Takes Center Stage in COVID-19 Vaccine and Cancer Research
Having come to fame as the basis of the Moderna and Pfizer/BioNTech vaccines for COVID-19, messenger RNA — or mRNA — is in many ways the molecule of the moment.
News
Dana-Farber Cancer Institute Faculty Recognized as 2021 ASCO Leaders in Cancer Care
The American Society of Clinical Oncology (ASCO) recognized two Dana-Farber Cancer Institute researchers as winners of ASCO's Special Awards, the Society’s highest honors. The recipients of these awards have worked to transform cancer care around the world.
News
Study Uncovers Potent Immunotherapy Approach to Ovarian Cancer Treatment
Immune therapies declare open season on cancer, rousing immune system cells to take up an attack on tumors. But which immune cells join the hunt, which sit it out, and what happens within immune cells that causes them to go on the offensive?
Video
Study of SACI-IO for Triple Negative Metastatic Breast Cancer
Filipa Lynce, MD, provides an overview of a study at Dana-Farber Cancer Institute testing the safety and efficacy of sacituzumab govitecan (Trodelvy) with or without pembrolizumab (Keytruda) for patients with PD-L1-negative, triple-negative metastatic breast cancer.
News
Level of Chromosomal Abnormality in Non-small Cell Lung Cancer May Predict Response to Immunotherapy
Dana-Farber researchers find patients whose tumors have low aneuploidy levels often have better outcomes following treatment with immune checkpoint inhibitors.
News
Pediatric Fertility Preservation Program
At Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, we value the importance of fertility and reproductive health as it relates to long-term quality of life. As treatment for childhood cancers and blood disorders have improved, more and more survivors are entering their reproductive years and thinking about starting families of their own. The fertility preservation team will work closely with patients’ primary care team to ensure that a fertility consultation takes place as a part of the patient’s comprehensive work-up.